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Cystatin M/E is a member of a superfamily of
evolutionarily-related cysteine protease inhibitors that
provide regulatory and protective functions against
uncontrolled proteolysis by cysteine proteases.
Although most cystatins are ubiquitously expressed,
high levels of cystatin M/E expression are mainly
restricted to the epithelia of the skin (epidermis, hair
follicles, sebaceous glands, and sweat glands) and to a
few extracutaneous tissues. The identification of its
physiological targets and the localization of these
proteases in skin have suggested a regulatory role for
cystatin M/E in epidermal differentiation. In vitro
biochemical approaches as well as the use of in vivo
mouse models have revealed that cystatin M/E is a key
molecule in a biochemical pathway that controls skin
barrier formation by the regulation of both cross-
linking and desquamation of the stratum corneum.
Cystatin M/E directly controls the activity of cathepsin
V, cathepsin L, and legumain, thereby regulating the
processing of transglutaminases. Misregulation of this
pathway by unrestrained protease activity, as seen in
cystatin M/E-deficient mice, leads to abnormal stratum
corneum and hair follicle formation, as well as to
severe disturbance of skin barrier function. Here, we
review the current knowledge on cystatin M/E in skin
barrier formation and its potential role as a tumor
suppressor gene.
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INTRODUCTION
Skin is our largest organ and plays an important protective
and esthetic role. It is the interface of the body with the
environment and consists of a stratified, keratinizing epithe-
lium anchored to a basement membrane. The underlying
connective tissue layer, the dermis, contains the vascular
network, the hair follicles, the sweat glands, and the
sebaceous glands. To protect the body against the invasion
of microorganisms, penetration of toxic agents, and loss of
essential body fluids, the skin has evolved an intricate
differentiation process that results in a tough, water-imperme-
able outer covering that is constantly renewing. The outcome
of this epidermal differentiation process is an organized tissue
in which morphologically distinguishable cells are arranged
in discrete layers of basal, spinous, granular, and cornified
cells (Archer, 1998; Eady et al., 1998).
As keratinocytes terminally differentiate, rupture of the
stratum granulosum cell integrity results in the release of
lysosomal proteases into the cytoplasm that eventually cause
cell death. These cells that have lost their nuclei and
cytoplasmic organelles are now called corneocytes and form
the stratum corneum. The corneocyte contains a stable and
insoluble cornified envelope that was synthesized just
beneath the disintegrating plasma membrane. This cornified
envelope consists of several specific proteins that are cross-
linked together in an orchestrated way by Ca2þ -dependent
transglutaminases (TGMs). The terminal stage of the differ-
entiation process is desquamation, which involves degrada-
tion of lipids in the intercellular spaces and loss of residual
intercellular desmosomal connections. Cells reaching the
skin surface, which consist largely of dead proteinaceous sacs
of keratin intermediate filament cables, are continuously
sloughed and replaced by inner cells differentiating and
moving outward (Reichert et al., 1993; Fuchs and Raghavan,
2002; Candi et al., 2005; Segre, 2006).
A model for the assembly of the epidermal cornified envelope
Biochemical studies have led to a model for cornified
envelope assembly that consists of three principal stages:
(i) initiation of cornified envelope assembly; (ii) formation of
the corneocyte lipid envelope; and (iii) reinforcement of the
cornified envelope (Nemes and Steinert, 1999; Kalinin et al.,
2001, 2002). As intracellular Ca2þ concentrations increase
in suprabasal cells, envoplakin, periplakin, and involucrin
are expressed, which then associate with keratin intermediate
filaments and desmosomal junctions. Nearly at the same
time, TGM1 is expressed, which docks into the plasma
membrane where it catalyzes the intrachain head-to-head
and head-to-tail crosslinking of involucrin, as well as
interchain crosslinking between both plakins and involucrin.
These events first occur at interdesmosomal sites on the cell
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membrane, and eventually, involucrin and the plakin proteins
(and perhaps other proteins) develop a monomolecular layer
along the entire inner surface of the plasma membrane,
including the desmosomes, thereby forming a scaffold. The
second step in this model is the formation of the corneocyte
lipid envelope. At a particular time point, perhaps coincident
with the initiation of scaffold assembly, lamellar granules are
thought to fuse with the plasma membrane of the granular cell
and discharge their lipid membranes into the intercellular space
to form a water-repelling envelope around the cornified
envelope. Finally, other structural proteins, including loricrin
and small proline-rich proteins, which together comprise about
80% of the total mass of the cornified envelope, are crosslinked
onto the scaffold to reinforce the initial structure. The cytosolic,
activated TGM3 enzyme catalyzes the homodimerization of
loricrin and the heterotrimerization of loricrin and small proline-
rich proteins, which are subsequently translocated to the border
of the cell, where TGM1 crosslinks them onto the preexisting
scaffold. Minor amounts of other proteins (cystatin A, SKALP/
elafin, LEP/XP5 proteins, repetin, and trichohyalin) also become
crosslinked to the cornified envelope. The last stage of the
cornified envelope assembly is characterized by rupture of the
cell integrity, which results in degradation of most cell
organelles and internal structures. Finally, the
dead cornified cells are shed from the skin by a process
called desquamation. Taken together, the complete
cornified envelope, consisting of the protein and lipid envelope,
and the intercellular lipid lamellae provide the vital mechanical
and water barrier functions for the skin and entire organism.
Lysosomal proteases and their inhibitors in skin
The analysis of the pathophysiology of inflammatory diseases,
genetic diseases, the invasive and metastatic mechanism of
malignant neoplasms, and the course of infectious diseases
has revealed that fundamental knowledge of the regulatory
mechanisms of proteases and their inhibitors is crucial for our
understanding of these diverse problems (Turk et al., 2002b;
Mohamed and Sloane, 2006; Lopez-Otin and Bond, 2008).
Regulation of proteolytic enzyme activity is essential for cells
and tissues at many levels (activation, compartmentalization,
and specific inhibition) because proteolysis at a wrong time
and location may have disastrous consequences.
Lysosomal cysteine proteases were long considered to be
primarily responsible for intralysosomal protein degradation,
mediating ‘‘housekeeping’’ functions in the cell. However,
numerous investigations have shown that classical cathepsins
are involved in a variety of physiological processes, such as
proenzyme activation, enzyme activation, antigen presenta-
tion, hormone maturation, tissue remodeling, and bone
matrix resorption (Dickinson, 2002). Recent studies also
suggest that cathepsins act as mediators of programmed cell
death, and have shown apoptosis pathways to be dependent
on lysosomal cathepsin activity (Stoka et al., 2001; Lippens
et al., 2005). Cathepsins are synthesized as pre-proenzymes
that are post-translationally glycosylated and phosphorylated
to active enzymes. Disturbance in their transport to lyso-
somes could lead to cytosolic protease activity or secretion of
the proenzyme to the extracellular matrix. Although an acidic
pH is optimal for the activity of lysosomal cysteine proteases,
individual enzymes are active over different pH ranges
(Chapman et al., 1997; Honey and Rudensky, 2003).
The regulation of the activity of cysteine proteases for correct
functioning is a fragile balance of many factors, one of the most
crucial being their cognate protease inhibitors, which include
members of the cystatin gene family. Cystatins are small proteins
that are widely distributed in several human tissues and body
fluids. They are generally tight-binding inhibitors of cysteine
proteases, such as cathepsins B, L, H, K, and S (Abrahamson
et al., 2003), and should therefore serve a protective function to
regulate the activities of such endogenous proteases. It is thought
that cysteine proteases and their inhibitors play an important
role in pathophysiological processes, such as invasion of normal
tissues by tumors or microorganisms, viral infections, and
inflammation (Korant et al., 1986; Bjorck, 1990; Calkins and
Sloane, 1995; Henskens et al., 1996). Cystatins are members of
a superfamily of evolutionarily-related proteins and can be
divided into three major families, namely family-1 cystatins (A
and B), family-2 cystatins (C, D, F, G, M/E, S, SN, and SA), and
the kininogens (L- and H-kininogens), which belong to family-3
cystatins. In general, cystatins are competitive, reversible, tight-
binding proteins that inhibit cysteine proteases in a micromolar
to picomolar range (Turk et al., 1997). Cystatins are viewed as
‘‘emergency’’ inhibitors, which mean that they rapidly trap a
protease without delay and keep it in a stable complex,
preventing any additional proteolysis (Bode and Huber, 2000;
Turk et al., 2002b). In normal situations, such an inhibitor would
have a physiological concentration in large excess over the
putative protease target(s). These inhibitors are in general
physically separated from their target proteases and primarily
act on escaped endogenous proteases or exogenous proteases of
invading microorganisms.
Interestingly, an increase in lysosomal cysteine protease
activity has been observed in the terminal differentiation process
of keratinocytes (Tanabe et al., 1991; Kawada et al., 1997).
Recent studies have reported that lysosomal proteases play
important roles in physiological processes not restricted to
lysosomes only (Turk et al., 2002a). For example, protease
activity and regulation outside lysosomes potentially contribute
to the propagation of apoptosis, a process that is distinct from
terminal differentiation of the epidermis but nevertheless shares
some molecular and cellular features. The importance of
regulated proteolysis in epithelia (Zeeuwen, 2004a) is well
shown by the identification of the SPINK5 serine protease
inhibitor as the defective gene in Netherton syndrome (MIM
256500) (Chavanas et al., 2000), cathepsin C (CTSC ) mutations
in Papillon–Lefevre syndrome (MIM 245000) (Toomes et al.,
1999), matriptase deficiency owing to mutations in the ST14
gene in ichthyosis with hypotrichosis syndrome (MIM 610765)
(Basel-Vanagaite et al., 2007), cathepsin L (CTSL) deficiency in
mice (Roth et al., 2000; Benavides et al., 2002; Tobin et al.,
2002), targeted ablation of cathepsin D (CTSD) in mice (Egberts
et al., 2004), and the phenotype of targeted epidermal
overexpression of the stratum corneum chymotryptic enzyme
in mice (Hansson et al., 2002).
To obtain a systematic and quantitative overview of genes
expressed by human epidermal cells, our group has
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previously established transcriptomes of cultured human
keratinocytes and purified epidermal cells through Serial
Analysis of Gene Expression and microarrays (GEO (Gene
Expression Omnibus) Series accession nos. GSE31 and
GSE6601). These analyses revealed quantitative expression
data on numerous proteases and protease inhibitors (Jansen
et al., 2001; van Ruissen et al., 2002a, b). Cystatin M/E, a
protein not known earlier to be expressed in human
keratinocytes, was found at considerable levels in these
analyses. Cystatin M was initially identified by differential
display as a downregulated mRNA in metastatic breast tumor
cells when compared with normal and primary breast tumor
cells (Sotiropoulou et al., 1997). Independently, the same
molecule was found by others through expressed sequence
tag sequencing in cDNA libraries derived from epithelial
cells, and was designated cystatin E (Ni et al., 1997). It was
shown that it was really a protease inhibitor, as the
recombinant protein was able to inhibit the plant protease
papain. However, in vivo target proteases and the function of
this protease inhibitor were unknown. Since then, investiga-
tions have been performed to study: (i) the molecular and
biochemical characteristics of cystatin M/E gene and protein;
(ii) the cellular aspects of cystatin M/E, for example, tissue
localization, distribution, and compartmentalization; (iii) the
cell biological and physiological functions of cystatin M/E;
and (iv) the role of cystatin M/E in epidermal homeostasis and
in disease. These investigations are reviewed here.
STRUCTURE AND EXPRESSION OF HUMAN CYSTATIN
M/E
Cystatin M/E is a 14 kDa secreted protein that shares only
35% homology with the human family-2 cystatins. Cystatin
M/E has an overall structure similar to other family-2
cystatins, such as a signal peptide and two intrachain
disulfide bonds, but possesses the unusual characteristic of
being a glycoprotein. This protein is only distantly related to
the other known family members as reflected by the genomic
position of the cystatin M/E gene on chromosome 11q13
(Stenman et al., 1997), whereas all other family-2 cystatin
genes are clustered in a narrow region on chromosome
20p11.2 (Schnittger et al., 1993). The full-length cystatin M/E
gene was cloned and sequenced, and deposited as CST6 in
the GenBank database (accession no. AY145051) (Zeeuwen
et al., 2003). The cystatin M/E gene is organized in three
exons and two introns, and from the translation start site to
the translation termination site it spans 1,354 bp of genomic
DNA. Characterization of the genomic sequence of cystatin
M/E shows some differences compared with that of the other
type 2 cystatins. The size of both introns was remarkably
smaller compared with that of other cystatin family-2
members (for example, cystatin S, SA, SN, C, and D). These
cystatins harbor introns of 1.1–2.2 kb, whereas the introns of
the cystatin M/E gene are only 542 and 365 bp long. Besides,
these family-2 cystatins contain an identifiable TATA box in
their 50-flanking sequence, whereas cystatin M/E lacks this
conserved sequence. Database analysis predicted three
transcription start sites at 75, 42, and 34 bp, respec-
tively, upstream to the translation initiation codon. This is in
accordance with the average length of the expressed
sequence tags found in the public database, in which the
start positions vary between approximately 60 and 20 bp.
The expression pattern of human cystatin M/E is unique
among cystatins, as high expression levels are largely
confined to cutaneous epithelia, whereas other cystatins are
mainly ubiquitously expressed. In human skin, cystatin M/E is
expressed in the differentiating and cornifying layers of the
epidermis (Figure 1) (Zeeuwen et al., 2001, 2007). This is in
accordance with the observation that, in vitro, cystatin M/E is
expressed only in differentiating but not in proliferating
keratinocytes (Zeeuwen et al., 2001). Cystatin M/E, which has
a putative signal peptide, is indeed a secreted protein and is
found in vitro in culture supernatant and in vivo in human
sweat and semen (Zeeuwen et al., 2001; Tjabringa et al.,
2005). Furthermore, cystatin M/E is also highly expressed in
the appendages of the skin, such as the secretory coils of the
eccrine sweat glands, the sebaceous glands, and the hair
follicles (Cheng et al., 2008). Immunohistochemical data
have also shown a moderate expression of cystatin M/E in the
bronchi of the lung, the proximal tubuli of the kidney, and in
the cornea of the eye (Zeeuwen et al., 2004b). Recently, the
expression of cystatin M/E was analyzed in a large panel of
human tissues at the mRNA level by real-time quantitative
PCR, which is currently the most accurate method to detect
quantitative gene expression levels. These experiments
revealed that high cystatin M/E mRNA expression was seen
in the skin, whereas moderate-to-low levels were observed in
the esophagus, oropharyngeal tissues, bronchus, lung, and
kidney (Cheng et al., in press). Cystatin M/E protein
expression was also reported recently in normal human
breast tissue (Rivenbark et al., 2007), breast ductal epithelium
(Ai et al., 2006), and in oligodendrocyte-like cells and
astrocyte-like cells of normal human brain (Qiu et al., 2008).
CYSTATIN M/E-DEFICIENT MICE
Analysis of adult mouse tissues revealed an expression
pattern that is less restricted than that observed earlier in
humans (Zeeuwen et al., 2002b). Relatively high levels of
Figure 1. Cystatin M/E expression in normal human skin. Formalin-fixed
section of normal human skin was stained by rabbit anti-cystatin M/E
antiserum (Zeeuwen et al., 2001). Staining is limited to the stratum
granulosum. Bar¼100 mm.
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cystatin M/E mRNA expression were found in the skin, ileum,
stomach, eye, and cerebellum; moderate-to-low levels of
expression were found in the tongue, palatum, nasal cavity,
colon, bladder, skeletal muscle, placenta, and thymus.
During embryogenesis, mRNA expression of cystatin M/E
was observed from day 16 onward, which is a developmental
stage where epidermal stratification is completed. Cystatin
M/E protein was found to be highly expressed in the ciliated
tracheal epithelium and in bronchial epithelium. Similar to
the expression pattern in humans, cystatin M/E was found in
the infundibular epithelium of hair follicles and in the stratum
granulosum of interfollicular epidermis. The mouse cystatin
M/E gene, which was subsequently cloned and characterized
(deposited as Cst6 in the GenBank database, accession no.
AY093591), has an exon–intron structure identical to that of
all other type 2 cystatins and encodes a 149-amino-acid
protein (Zeeuwen et al., 2002b). Alignment with its presumed
human ortholog revealed 69% amino-acid identity and 82%
amino-acid conservation. The chromosomal localization of
mouse cystatin M/E was determined by fluorescence in situ
hybridization and mapped to the proximal end of chromo-
some 19, a region that is syntenic to human chromosome
11q13 where the human cystatin M/E gene resides.
With the knowledge of the cystatin M/E tissue expression
and the locus of the gene in mice, it was hypothesized that
cystatin M/E could be a candidate gene for the ichq mouse, a
naturally occurring mutant laboratory mouse (Figure 2). This
mouse had morphological and biochemical similarities to a
human form of ichthyosis caused by an unknown gene defect
(Sundberg et al., 1997). This hypothesis was confirmed by
the identification of a mutation in the cystatin M/E gene of
these ichq mice (Zeeuwen et al., 2002b). Homozygosity for a
single nucleotide deletion in exon 1 of the cystatin M/E gene
was identified in these mutant mice. This 42delG deletion
alters the reading frame, resulting in a premature stop codon
at amino acid position 20. Immunohistochemistry confirmed
the absence of cystatin M/E at the protein level in ichq mice.
Mice that were homozygous for two null alleles displayed a
hyperplastic, hyperkeratotic epidermis and abnormal hair
follicles, and died between 6 and 12 days of age. Hetero-
zygous mice and wild-type littermates displayed a normal
cystatin M/E expression pattern, suggesting that cystatin M/E
functions as an inhibitor of hitherto unidentified proteases.
The mouse ichq mutant is another example of a disturbed
protease–antiprotease balance causing faulty differentiation
processes in the epidermis and hair follicle. Other examples
of dysregulated proteases and protease inhibitors leading to
abnormal cornification include SPINK5, matriptase, cathe-
psin C, caspase 14, and CTSD (Toomes et al., 1999;
Chavanas et al., 2000; Egberts et al., 2004; Basel-Vanagaite
et al., 2007; Denecker et al., 2007).
At this point, the next goal was to identify the putative target
protease(s) for cystatin M/E and to investigate the mechanism by
which the absence of cystatin M/E causes epidermal abnorm-
alities in ichq mice. The additional questions that arose from
these investigations were (i) which proteins are processed by the
target protease(s)?; (ii) which biological processes are regulated
by the target protease(s)?; and (iii) which processes are disturbed
by their unrestricted protease activity as was probably the case
in cystatin M/E-deficient mice?
PHYSIOLOGICAL TARGETS OF CYSTATIN M/E
Biochemical studies have indicated that cystatin C and
cystatin M/E in vitro bind with high affinity to the asparaginyl
endopeptidase legumain (LGMN) (Alvarez-Fernandez et al.,
1999). This was an unexpected finding, as cystatins were
primarily regarded as inhibitors of papain-like cysteine
proteases in the unrelated family C1 (Abrahamson et al.,
2003). LGMN belongs to the family C13 of cysteine proteases
and is strictly specific for hydrolysis of asparaginyl bonds
(Chen et al., 1997). Furthermore, this lysosomal protease was
shown to be involved in the processing of other lysosomal
proteases, such as cathepsins B, H, and L (Shirahama-Noda
et al., 2003; Maehr et al., 2005). Although cystatin M/E
contains a predicted binding site for papain-like cysteine
proteases, the first reports only showed moderate-to-low
inhibition activity toward human cathepsin B (Ni et al., 1997;
Zeeuwen et al., 2001). Recently it was shown that cystatin
M/E is a high-affinity inhibitor of cathepsin V (CTSV) and
CTSL by a reactive site that is distinct from the LGMN-binding
site (Cheng et al., 2006). These kinetic studies have shown
that Ki values of cystatin M/E for the interaction with CTSV
and CTSL are 0.47 and 1.78 nM, respectively.
CTSV is a recently discovered protease, also known as CTSL2
or stratum corneum thiol protease. CTSV is closely related to
CTSL, and these proteins shareB80% sequence identity (Adachi
et al., 1998; Santamaria et al., 1998; Bromme et al., 1999;
Watkinson, 1999). Their encoding genes are located on adjacent
sites on chromosome 9q22.2, suggesting that CTSV and CTSL
have evolved by duplication from an ancestral gene. However,
although CTSL is ubiquitously expressed, human CTSV expres-
sion is more restricted and predominantly found in the thymus,
testis, cornea of the eye, and epidermis. Besides the general
function of lysosomal cathepsins, that is bulk proteolysis, studies
using a knockout mouse model have suggested that CTSL has
specific functions in keratinocyte proliferation and hair follicle
morphogenesis and cycling (Roth et al., 2000; Benavides et al.,
2002; Tobin et al., 2002). Recently, the phenotype of CTSL
Figure 2. Phenotype of ichqmice. Cystatin M/E-deficient mice (9 days of age)
are covered with white scales that start to appear at day 5 on the dorsal skin,
just behind the neck. The mice die between days 6 and 12 from dehydration.
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knockout mice was rescued by transgenic epidermal re-
expression of either murine CTSL or human CTSV, indicating
that human CTSV can compensate for murine CTSL (Hagemann
et al., 2004). No ortholog of CTSV in mice has been discovered
yet, but it is likely that murine CTSL is actually the ortholog of
human CTSV, in view of the fact that human CTSV is
phylogenetically more closely related to murine CTSL than to
human CTSL (Reinheckel et al., 2005).
On the basis of the analogous sites in cystatin C (Alvarez-
Fernandez et al., 1999), site-directed mutagenesis was used
to identify the presumed binding sites of these cathepsins and
LGMN in human cystatin M/E. Substitution of a conserved
amino acid by alanine in the two reactive sites resulted in the
loss of inhibitory activity. It was shown that the W135A
cystatin M/E mutant was rendered inactive against CTSV and
CTSL but retained LGMN-inhibiting activity. Conversely, the
N64A mutant lost LGMN-inhibiting activity but remained
active against the papain-like cysteine proteases, which
means that LGMN and both papain-like cysteine proteases
are inhibited by two distinct non-overlapping sites (Cheng
et al., 2006). The presumed role of LGMN, CTSV, and CTSL
in terminal differentiation of keratinocytes and hair follicle
morphogenesis is that these proteases process and activate
other enzymes in pathways that lead to skin barrier formation
(see the section Cystatin M/E: function and regulation).
CYSTATIN M/E: FUNCTION AND REGULATION
Cystatin M/E-deficient mice show defects in epidermal corni-
fication and die between 6 and 12 days of age (Sundberg et al.,
1997; Zeeuwen et al., 2002b). Autopsy on neonatal ichq mice
strongly suggested that these mice died of dehydration, probably
owing to a disturbed skin barrier function (Zeeuwen et al.,
2004a). It was shown that the transepidermal water loss through
the skin of the cystatin M/E-deficient mice is increased when
compared with phenotypically normal littermates. In addition, a
progressive weight loss was observed in the cystatin M/E-
deficient mice starting at the time point at which transepidermal
water loss was apparent. At day 11, body weights wereB50%
compared with normal littermates, and most mice died shortly
thereafter (Zeeuwen et al., 2004a).
Morphological and functional analysis has indicated a
compromised stratum corneum and aberrant cornification of
the hair follicles in cystatin M/E-deficient mice, which could
be the result of abnormal expression or processing of
structural components of the cornified envelope. In two
earlier studies, no abnormalities were found in structural
proteins such as cytokeratins, involucrin, and filaggrin
(Sundberg et al., 1997; Dunnwald et al., 2003). This was
investigated again by studying the expression and distribution
of loricrin, involucrin, and filaggrin, which are important
stratum corneum proteins that are involved in skin barrier
function. Immunohistochemical analysis showed that all
three proteins are normally expressed in the skin of cystatin
M/E-deficient mice. However, western blot analysis revealed
that loricrin monomers and loricrin dimers are strongly
diminished in skin extracts of cystatin M/E-deficient mice
(Zeeuwen et al., 2004a). Collectively, these findings suggest
misregulated crosslinking of loricrin monomers.
As described earlier in the Introduction section, it is
known that the cytosolic, activated TGM3 enzyme is
responsible for the crosslinking of loricrin molecules. The
resulting homodimers and heterodimers are subsequently
translocated to the periphery of the cell, where TGM1
crosslinks them onto the preexisting scaffold. Proteolytic
cleavage of TGM3 is required to achieve maximal-specific
activity of the enzyme (Kim et al., 2001), and one important
question was how TGM3 could be processed into its active
form. TGM3 activation during keratinocyte differentiation
involves cleavage of the 77 kDa zymogen by an unknown
protease resulting in the release of 30 and 47 kDa fragments,
which then associate and form the active enzyme (Ahvazi
et al., 2002). Western blot analysis revealed an abundant
presence of proteolyzed (and hence activated) TGM3 in skin
extracts of cystatin M/E-deficient mice at day 6, whereas no
appreciable levels of proteolyzed TGM3 could be detected in
skin extracts of wild-type littermates (Zeeuwen et al., 2004a).
This indicated that premature, high levels of activated TGM3
are present at the time when skin lesions develop in cystatin M/
E-deficient mice. It was hypothesized that cystatin M/E controls
the activity of an unknown protease that is responsible for
TGM3 activation, which leads to crosslinking of loricrin
molecules and skin barrier formation. If cystatin M/E is missing
in the skin, unrestrained protease activity is followed by too
much, and too early activity of TGM3, probably leading to
pathology as seen in cystatin M/E-deficient mice.
Subsequently, it was investigated whether human LGMN
could process human recombinant TGM3 in vitro into its
active form. LGMN was the first candidate because localiza-
tion of free LGMN activity was found in the stratum
granulosum and in the infundibular part of the hair follicle
in cystatin M/E-deficient mice. This matches the reported
localization of tissue pathology in these mice, such as
excessive cornification in hair follicles and epidermis,
leading to plugging of the hair follicle and ichthyosis. No
LGMN activity could be shown in the skin of wild-type
littermates, which suggested that the presence of cystatin M/E
normally regulates LGMN activity in skin in vivo (Zeeuwen
et al., 2004a). It was found that TGM3 was slowly processed
into its active form by a human kidney extract as detected by
mAbs directed against the human zymogen and the 30 and
47 kDa fragments. As no active recombinant LGMN was
available at that time, human kidney extract was used as a
source of LGMN activity. Proteolytic processing of recombi-
nant TGM3 by the human kidney extract could be completely
inhibited by a specific LGMN inhibitor Cbz-Ala-Ala-Aasn-
EP-COOEt. As it is known that LGMN affects processing of
lysosomal cathepsins (Shirahama-Noda et al., 2003; Maehr
et al., 2005), it was considered that LGMN possibly mediates
processing of TGM3 in an indirect manner. Indeed, using
compound E-64, a synthetic broad-spectrum inhibitor of
lysosomal cysteine proteases that is not effective against
LGMN, a complete inhibition of TGM3 processing was
found. This finding was addressed in further detail by
investigating the in vitro processing of TGM3 by a panel of
purified lysosomal cysteine proteases (Cheng et al., 2006). It
was shown that CTSL is the elusive protease that can process
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and activate TGM3, whereas other cathepsins (B, D, S, and V)
were not able to cleave the TGM3 zymogen. It was shown
that cleavage by CSTL causes a biologically active TGM3
molecule, whereas unprocessed TGM3 did not show any
activity. N-terminal sequencing of the 30 kDa TGM3
fragment revealed that the CTSL cleavage site in TGM3 is
between amino acids Ala466 and Ala467. As CTSL preferen-
tially cleaves peptide bonds with aromatic residues in the P2
and hydrophobic residues in the P3 position (Barrett et al.,
2004), this is most likely the exact cleavage site of human
TGM3. This conclusion was based on the fact that, in the P2
and P3 positions of the TGM3 cleavage site, an aromatic
residue (Phe465) and a hydrophobic residue (Pro464), respec-
tively, are found. Future studies should clarify whether this is
the physiological cleavage site in vivo as well.
To further address the possible role of cystatin M/E and its
physiological target proteases in epidermal differentiation,
the exact localization and compartmentalization of these
proteins was investigated by immunofluorescence micro-
scopy (Zeeuwen et al., 2007). Although CTSL and LGMN
were broadly expressed in the cytoplasm of the epithelial
cells of the skin, a specific colocalization of cystatin M/E and
CTSV was found in the stratum granulosum and in the root
sheath of the hair follicles, showing a typical granular pattern
(Figure 3). Immunoelectron microscopy revealed that cystatin
M/E and CTSV are separately transported within the lamellar
granules. Recently, it was shown that epidermal lamellar
granules transport different cargoes (for example, CTSD,
glucosylceramides, corneodesmosin, and KLK7) as distinct
aggregates, which were delivered to the apical region of
granular keratinocytes (Ishida-Yamamoto et al., 2004). One
could speculate that separate transport of cystatin M/E and
CTSV by lamellar granules may prevent interaction within the
cells. Moreover, cystatin M/E and CTSV are detected in the
extracellular spaces of the upper stratum corneum layers
where both proteins are associated with desmosomes,
suggesting that these molecules could have an important
role in desquamation, which is the final event in terminal
differentiation of the epidermis. During desquamation,
breakdown of lipids in the intercellular spaces and loss of
residual intercellular desmosomal connections lead to cell
shedding of the dead corneocytes from the stratum corneum
surface (Elias, 2005). A number of studies have shown the
involvement of different epidermal proteases in the progres-
sive degradation of the desmosomal proteins desmocollin-1,
desmoglein-1, plakoglobin, and corneodesmosin (Lundstrom
and Egelrud, 1990; Simon et al., 2001; Caubet et al., 2004).
As an acidic pH dominates in the outer stratum corneum
layers (Elias, 2004), it is conceivable that CTSV activity in
these layers fulfills a significant function in the desquamation
process (for example, degradation of desmosomal constitu-
ents), as opposed to serine proteases that mainly act in the
neutral pH environment of the lower stratum corneum layers.
This was supported by in vitro experiments that showed
degradation of corneodesmosomal proteins by CTSV at an
acidic pH, whereas no degradation products were observed,
as reactions were performed at a neutral pH of 7 (Cheng
et al., in press).
Taken together, these data suggest a mechanism in which
cystatin M/E is a key molecule in a biochemical pathway that
controls skin barrier formation by the regulation of both
crosslinking and desquamation of the stratum corneum
(Figure 4). First, cystatin M/E could have a role in desquama-
tion by the regulation of CTSV protease activity, which is
involved in the degradation of corneodesmosomal compo-
nents. Second, cystatin M/E could regulate crosslinking of
structural proteins by TGM3 in the cornification process of
the epidermis and the hair follicle by controlling CTSL and
LGMN activities. Furthermore, cystatin M/E might also be
involved in the regulation of TGM1 activity, as it is known
that CTSL can process and activate CTSD (Wille et al., 2004;
Laurent-Matha et al., 2006). It has been reported that CTSD,
an aspartate protease, is involved in the regulation of TGM1
(Higuchi et al., 2001; Egberts et al., 2004). In vitro
experiments have shown that TGM1 activity is stimulated
by exogenous CTSD in cultured keratinocytes, and that in
CTSD-deficient mice, a reduced TGM1 enzymatic activity
and defective TGM1 processing were observed. The regula-
tory role of cystatin M/E in the cornification process of the
epidermis was further supported by the observation that, in
skin extracts of 6- to 12-day-old cystatin M/E-deficient mice,
relatively high levels of proteolyzed CTSD and TGM1 are
found, whereas no appreciable levels of these proteolyzed
proteins could be detected in skin extracts of wild-type
Figure 3. Colocalization of cystatin M/E and CTSV in human epidermis and
hair follicle. Immunofluorescence double staining (yellow-orange merge
color) for cystatin M/E (green) and CTSV (red) in the (a) epidermis and a
transversal section of the (b) hair follicle. DNA staining by DAPI (blue).
Bar¼50 mm.
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littermates (Zeeuwen et al., 2004b). Furthermore, increased
levels of mainly membrane-bound TGM activity (in situ) were
observed in 6- to 12-day-old cystatin M/E-deficient mice,
suggesting that increased TGM1 activity could be involved in
the pathology of these mice, which is clearly a direction for
future research. In addition, regulation of CTSD activity is
also important in the desquamation process of the skin, as the
mature active form of CTSD is able to degrade desmosomal
components (Horikoshi et al., 1999).
Recent epigenetic studies have provided evidence that
regulation of cystatin M/E gene expression is regulated by
methylation of the CpG islands present in the cystatin M/E
proximal promoter region and exon 1 (Ai et al., 2006;
Rivenbark et al., 2006; Schagdarsurengin et al., 2007; Qiu
et al., 2008). Methylation of CpG islands is a postreplicative
modification thought to play a role in gene transcription in
eukaryotes, either through interference with transcription
factor binding or through the recruitment of repressors that
specifically bind sites containing methylated CpG. A growing
number of human diseases have been found to be associated
with aberrant DNA methylation (Robertson, 2005; Feinberg,
2007). It was reported that cystatin M/E expression is
frequently silenced in breast carcinomas by epigenetic
inactivation related to DNA methylation (see section Cystatin
M/E and cancer for details).
CYSTATIN M/E AND DISEASE
Ichthyosis
The ichq mouse phenotype includes hyperkeratosis, abnor-
mally large mitochondria, and absence of lamellar granules
(Sundberg et al., 1997); some of these morphological and
biochemical features are similar to human type 2 harlequin
ichthyosis (HI, MIM 242500), suggesting that the ichq mouse
might be a good model for the human disorder. The
involvement of cystatin M/E in HI in humans was evaluated
by sequencing the entire coding region and intron–exon
boundaries for mutations in 11 sporadic HI patients
(Zeeuwen et al., 2003). No cystatin M/E mutations were
detected in this group, which comprised types 1 and 2 HI
patients. Disturbed transcription/translation owing to muta-
tions in regulatory and non-coding regions of cystatin M/E
was unlikely because cystatin M/E protein expression was
observed in all patients examined, as assessed by immuno-
histochemistry. These data have indicated that cystatin M/E is
unlikely to be a major gene responsible for types 1 and 2 HI.
Recently, it was discovered that mutations in ABCA12, a
member of the ATP-binding cassette transporter superfamily,
underlie congenital HI (Kelsell et al., 2005). It was reported
that ABCA12 works as an epidermal keratinocyte lipid
transporter and that defective ABCA12 results in a loss of
the skin lipid barrier, leading to HI (Akiyama et al., 2005).
However, cystatin M/E and the genes that have a role in
biological pathways that are controlled by cystatin M/E
should be considered as candidate genes for human disorders
of cornification of unknown etiology, especially for lamellar
ichthyosis (LI, MIM 242300), ichthyosis vulgaris (IV, MIM
146700), and other ichthyosiform conditions. An immuno-
histochemical evaluation for cystatin M/E protein expression,
followed by mutation analysis of all cystatin M/E exons
including exon/intron boundaries, was performed on a
number of cornification disorders (LI n¼15; IV n¼ 5; HI
n¼3, Netherton syndrome n¼2) (Oji et al., 2005). Cystatin
M/E expression was observed in the stratum granulosum in
most cases of LI, including those showing TGM1 deficiency.
Inactive legumain
Cystatin M/E
Inactive (pro)cathepsins
Active legumain Active cathepsins CTSV
CTSL
Degradation of
(corneo)-desmosomal proteins
Desquamation
DSG1
DSC1
CDSN
TGM3
zymogen
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Figure 4. Regulation of epidermal protease activity by cystatin M/E. A simplified scheme of the presumed regulatory role of cystatin M/E in processes that
control epidermal cornification and desquamation. Cystatin M/E is an inhibitor of the asparaginyl endopeptidase LGMN and the cysteine proteases CTSL and
CTSV. Inhibition of LGMN might regulate the processing of (pro)-cathepsins, a process that is also under the control of intra- and extracellular pH changes.
Inhibition of CTSV putatively regulates desquamation, as CTSV is able to degrade (corneo)-desmosomal proteins such as desmoglein-1 (DSG1), desmocollin-1
(DSC1), and corneodesmosin (CDSN). Inhibition of CTSL activity by cystatin M/E is thought to be important in the cornification process, as CTSL is the elusive
processing and activating enzyme for TGM3. CTSL is also able to process CTSD, an aspartate protease that can regulate TGM1 activity.
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Three patients with LI had a faint staining, whereas in HI
protein expression was normal. In contrast, skin sections of IV
also displayed a signal of cystatin M/E in the upper layer of the
epidermis including the stratum corneum. Interestingly, one
individual with LI presenting an enhanced epidermal expres-
sion of cystatin M/E showed a mutation on one allele in exon 1
(AA110TT) resulting in an amino-acid change from glutamic
acid to valine (E37V) next to the reactive site of the proteinase
inhibitor, which makes it plausible that the cystatin M/E
inhibitory activity is reduced in this patient. This mutation was
absent in 90 different control chromosomes. Interestingly, this
patient was also heterozygous for a filaggrin mutation, which is
the major predisposing factor for IV and atopic dermatitis
(Palmer et al., 2006; Smith et al., 2006). Patients heterozygous
for a filaggrin mutation normally show a mild skin phenotype;
however, this patient was characterized by a severe ichthyosis
phenotype. This suggested that the heterozygous E37V
mutation in the cystatin M/E gene in combination with
heterozygosity for filaggrin might be responsible for the severe
skin phenotype. Therefore, site-directed mutagenesis was
performed to produce a recombinant cystatin M/E variant in
which the Glu37 residue was substituted for a Val residue.
However, no reduced cystatin M/E inhibitory activity against
CTSV and CTSL was found compared with wild-type cystatin
M/E. This indicates that the heterozygous E37V mutation found
in the LI patient does not disturb the presumed binding site of
cathepsins (Zeeuwen et al., 2004b).
Hair follicle-related diseases
Cystatin M/E-deficient mice show a severe skin and hair
phenotype characterized by defects in cornification processes,
suggesting that regulation of protease activity by cystatin M/E is
important not only in the skin but also in terminal differentiation
of the hair follicle, and that disturbance could lead to abnormal
development of this skin appendage. Therefore, heritable
genetic skin diseases that are characterized by hyperkeratiniza-
tion of hair follicles are candidate diseases for cystatin M/E
mutations. Cystatin M/E was found to be normally expressed at
the protein level in two patients with ichthyosis follicularis with
atrichia and photophobia (MIM 308205) (Cambiaghi et al.,
2002). No mutations were found in any of the cystatin M/E
exons or exon/intron boundaries. This study, and that of Oji
et al. (2005), who examined another case of ichthyosis
follicularis with atrichia and photophobia, excluded cystatin
M/E as the causative gene for this disease (Zeeuwen et al.,
2004b). Keratosis pilaris defines a group of cutaneous disorders
characterized by follicular hyperkeratosis and frequently
occurring with atopy or ichthyosis (MIM 604093). Keratosis
pilaris is a very common skin/hair follicle disease that can range
from minimal to severe forms. It is characterized by hyperker-
atinization of hair follicles, and as a result, the hair is prevented
from exiting the skin. Keratosis follicularis spinulosa decalvans
is a rare disorder affecting also the eye (MIM 308800). Although
most affected families are compatible with X-linked inheritance,
this disease appears to be genetically heterogeneous. We
speculate that the group of recessive keratosis pilaris disorders is
a possible candidate for cystatin M/E mutations, and as such
they are currently under investigation.
Inflammatory skin diseases
Atopic dermatitis and psoriasis are two common chronic
inflammatory skin diseases in which the expression of many
genes and the formation of the epidermal barrier are altered.
Although both diseases are generally regarded as immune-
mediated conditions, recent genetic studies have indicated
the importance of abnormalities in epithelium-expressed
genes as a primary cause. Loss-of-function alleles of the skin
barrier protein, filaggrin, were found to be a major predis-
posing factor for atopic dermatitis (Palmer et al., 2006), and it
was recently shown that a copy number polymorphism of a
b-defensin gene cluster and the deletion of the late cornified
envelope 3B and 3C genes were associated with increased
risk for psoriasis (Hollox et al., 2008; de Cid et al., 2009). In
view of the fact that the cystatin M/E–cathepsin pathway is
important for correct epidermal differentiation, the expres-
sion of all players of this biochemical pathway in these two
major inflammatory skin diseases was investigated (Cheng
et al., in press). Generally, mRNA expression levels of
cystatin M/E and CTSV are decreased in inflamed skin,
whereas the levels of CTSL and TGM3 are increased. These
findings are in accordance with microarray analyses in
patients with atopic dermatitis or psoriasis (GEO profiles
GDS2381 and GDS2518, accessible at the NCBI Gene
Expression Omnibus http://www.ncbi.nlm.nih.gov). De-
creased protein expressions of cystatin M/E and CTSV in
atopic dermatitis and psoriasis were confirmed by the
quantification of immunofluorescent stainings, but the
elevated transcriptional levels of CTSL and TGM3 were not
matched by increased protein expression (Cheng et al.,
in press). It was concluded that disturbance of the cystatin
M/E–cathepsin pathway could contribute to dysregulated
skin barrier function as observed in these inflammatory
dermatoses.
Cystatin M/E and cancer
Several studies have shown that cysteine proteases such as
cathepsin B and CSTL are involved in cancer through their
role in proteolytic pathways that enable tumor growth,
migration, invasion, and metastasis. This is supported by
increased cysteine protease expression in a wide variety of
cancers (Mohamed and Sloane, 2006). The importance of the
fine balance between cysteine proteases and their inhibitors
in cancer is further underlined by the abnormal expression of
cystatins in many types of tumors (Keppler, 2006).
Cystatin M/E was initially identified by differential display
as a downregulated mRNA in metastatic breast tumor cells
when compared with normal and primary breast tumor cells,
suggesting that loss of the expression of cystatin M/E is likely
associated with the progression of a primary tumor to a
metastatic phenotype (Sotiropoulou et al., 1997). This
hypothesis was tested in vitro by transfection of the highly
tumorigenic and metastatic human breast cancer cell line,
MDA-MB-435S, which normally does not express cystatin M/
E, with a cystatin M/E cDNA expression vector. The
constitutive cystatin M/E expression in transfected cells
resulted in a significant reduction of cell proliferation,
migration, Matrigel invasion, and endothelial cell adhesion
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(Shridhar et al., 2003). However, only cell migration and
matrix invasion appeared to be controlled by the inhibition of
cysteine protease activity, as the synthetic cysteine protease
inhibitor E-64 showed no effect on cell proliferation and
endothelial adhesion. This finding made the authors suggest
that cystatin M/E may act as a tumor and metastasis
suppressor through other mechanisms (than cathepsin inhibi-
tion), perhaps through its inhibitory effects on LGMN or even
through modulation of gene transcription. Cystatin M/E
expression in MDA-MB-435S cells significantly changed the
expression of several genes involved in tumor growth,
invasion, and angiogenesis, including downregulation of
autotaxin, a signaling molecule that has been linked to breast
cancer invasiveness (Song et al., 2006). Subsequently, the
transfected MDA-MB-435S cells were injected into scid mice
to test whether cystatin M/E expression might have in vivo
tumor-suppressing functions (Zhang et al., 2004). The mice
were analyzed for tumorigenesis and spontaneous metastasis
in the lungs and compared with mice implanted with mock
controls. During the first 45 days, scid mice bearing
orthotopically injected cystatin M/E-expressing MDA-MB-
435S cells developed significantly smaller tumors than mock-
injected controls; however, no difference was found in the
incidence of metastasis and the number of lesions in the
lungs. Cystatin M/E expression showed no effect on seeding
and survival of tumor cells, but reduced the growth of
established lung tumors, which suggests that cystatin M/E has
antiproliferative activity. One should keep in mind that there
is some controversy about the origin of the MDA-MB-435S
cancer cell line, as it was reported that these cells may be
derived from melanocytes and as such cannot be considered
with absolute certainty as a model for breast cancer (Ross
et al., 2000). Preliminary studies using laser-capture dissec-
tion of human breast cancer cells varied in outcome. Zhang
et al. (2004) reported a downregulation of cystatin M/E
mRNA and protein expression in invasive ductal carcinomas
compared with normal breast tissue, which is in contrast with
another study that showed cystatin M/E expression in most of
the breast carcinomas, including primary and metastatic
tumors (Vigneswaran et al., 2005). Recently, epigenetic
studies reported DNA methylation-dependent silencing of
the cystatin M/E gene in breast cancer cell lines, primary
breast tumors, and metastases. Hypermethylation, especially
of the proximal promoter, was significantly associated with
gene silencing and loss of cystatin M/E protein expression,
whereas treatment with the demethylating agent, 5-aza-
20deoxycytidine, induced cystatin M/E mRNA expression in
breast cancer cell lines (Ai et al., 2006; Rivenbark et al.,
2006; Schagdarsurengin et al., 2007). Cystatin M/E promoter
methylation (and loss of cystatin M/E protein expression)
occurred more frequently in lymph node metastases, whereas
primary tumors were found to be negative for cystatin M/E
promoter methylation. This suggests that epigenetic silencing
of cystatin M/E is involved in breast cancer tumorigenesis and
progression into metastasis (Rivenbark et al., 2007). Further-
more, it was recently shown that epigenetic silencing of
cystatin M/E is frequent in gliomas (Qiu et al., 2008). The
authors suggest that cystatin M/E methylation may therefore
represent a new prognostic marker and therapeutic target
specifically altered in glioma tumor-initiating cells.
Reduced or absent expression of cystatin M/E was also
found in basal cell carcinomas of the skin, squamous cell
carcinomas (SCCs) from the lung, and in lung cancer
(Zeeuwen et al., 2002a; Werle et al., 2006), but in
oropharyngeal SCCs, cystatin M/E expression was found to
be increased with metastasis along with elevated cathepsin
expression (Vigneswaran et al., 2003). Silencing of cystatin
M/E by small interference RNA in a metastatic oral cancer
cell line increased in vitro cell proliferation, migration, and
Matrigel invasion, emphasizing the tumor- and metastasis-
suppressing abilities of cystatin M/E (Vigneswaran et al.,
2006). Gene expression profiling of cutaneous SCCs and
psoriasis, a study designed to compare malignant versus
benign keratinocyte hyperproliferation, revealed that cystatin
M/E and several proteases were among the genes that were
significantly upregulated in SCCs (Haider et al., 2006).
Collectively these data suggest that cystatin M/E could act as
a tumor suppressor through various mechanisms of
action, including inhibition of cysteine protease activity and
modulation of gene transcription. However, it is not yet
clear what the exact role of cystatin M/E is in tumorigenesis
and metastasis, as both down- and upregulation have been
found depending on the type of cancer, suggesting that altered
cystatin M/E expression could either have a causative effect or
that it is alternatively a protective response. In an earlier study,
we concluded that cystatin M/E expression was a not a useful
marker to discriminate between benign (keratoacanthoma), pre-
malignant (actinic keratosis), and malignant epidermal neopla-
sias (basal cell carcinomas and SCCs). Cystatin M/E expression
in these skin-derived neoplasias appeared to be limited to the
keratinized and well-differentiated cells. SCCs from the lung
and the head and neck region were found to be negative for
cystatin M/E. However, one cutaneous metastasis of a head and
neck tumor was positive for cystatin M/E, suggesting that for
these squamous neoplasias a cutaneous environment is
necessary for cystatin M/E expression (Zeeuwen et al., 2002a).
CONCLUSIONS
The past few years have taught us a great deal on the role of
cystatin M/E and its cognate proteases in epidermal biology.
Currently, no human disease is known that is caused by
genetic alterations of the proteins in this newly discovered
pathway. Nevertheless, all unresolved heritable human skin
disorders that show faulty cornification, desquamation, and/
or hair follicle morphogenesis are candidates for cystatin M/E
deficiency, and the identification of such a disorder remains a
major challenge. As CTSV and CTSD are involved in the
breakdown of corneodesmosomal proteins, they could also
be candidate genes for ichthyosiform skin diseases that show
disturbed desquamation by retention of scales. In addition to
excessive TGM activity owing to cystatin M/E deficiency, as
seen in ichq mice, lack of TGM activity can also lead to
disturbed cornification as witnessed by the autosomal-
recessive ichthyosis LI in which mutations in TGM1 are
responsible for the disease (Huber et al., 1995). Although
TGM3 accounts for more than 75% of the total TGM activity
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in the epidermis (Kim et al., 1990), it cannot compensate for
cornified envelope formation in patients with LI in which
TGM1 activity is absent (Candi et al., 1998), probably
because crosslinking by TGM1 precedes crosslinking by
TGM3 according to the model for assembly of the cornified
envelope (see Introduction). Although this might seem
paradoxical at first glance, both loss and inappropriate gain
of TGM activity could explain ichthyotic changes, although
the mechanisms could be different. Excessive TGM1 and
TGM3 activity could lead to retention of scales by hyper-
crosslinked corneocytes, whereas deficiency for TGM1 could
lead to irregular scaling owing to lack of attachment of
involucrin to the o-hydroxyceramides. There are, however,
other forms that are clinically similar to LI but are not linked
to the locus of the TGM1 gene. The redundancy of TGM3 is
indicated by knockout mice that show no particular skin
phenotype (John, 2006). This leaves open the possibility that
mutations in genes that are involved in the processing of
TGMs into the active form might be causative for other forms
of ichthyosis. In conclusion, we suggest that cystatin M/E is a
candidate gene for heritable human skin disorders that show
faulty cornification and desquamation.
Recently, it was shown that human reconstructed skin is a
valuable tool for future research as it correctly recapitulates the
expression pattern of all players in the pathway (Cheng et al., in
press). Gene knockdown (by delivery of siRNA) or overexpres-
sion of certain genes by using lentiviral vectors would be an
option to further delineate the role of cystatin M/E and its target
proteases in the final steps of epidermal differentiation. Together
with the use of knockout mouse models that we are currently
generating (cystatin M/E–LGMN, cystatin M/E–CTSL, and cystatin
M/E–TGM3 double knockout mice), this work extends our
knowledge on the components that are involved in epidermal
cornification and desquamation. In addition, we are rescuing the
mutant cystatin M/E-deficient mice (neonatal lethal) by the
introduction of a transgene that drives epidermis-specific cystatin
M/E expression on a cystatin M/E null background. This will
enable us to study the consequences of cystatin M/E deficiency
on the physiology and maintenance of adult tissues. We expect
that these data will lead to further understanding of human
disorders characterized by disturbed skin barrier function.
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